Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Dabigatran; Rivaroxaban

Criteria

Inclusion Criteria:

• Healthy participants

• Aged between 18-35 years inclusive

• Male

• Caucasian

• Body mass index (BMI) between 18 and 27 kg per m² inclusive.